Valuation
- Market cap
- 229,166,000
- Revenue TTM
- $0
- Net income TTM
- $-248,230,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 4,076,500
- Avg volume
- 1,012,824
- Day's range
- $2.20 – $2.36
- Shares out
- 100,954,000
- Stochastic %K
- 52%
- Beta
- 1.07
- Analysts
- Strong Sell
- Price target
- $8.00
Company profile
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is...
Show more
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. As of May 21, 2025, Acelyrin, Inc. operates as a subsidiary of Alumis Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 805 456 4393
- Website
- https://www.acelyrin.com
- Address
- 4149 Liberty Canyon Road, Agoura Hills, United States
Latest news
No headlines yet.
